Tuesday, 3 December 2013

PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022


Reportstack has announced a new market report on PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022. Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.

The DES market in China is projected to grow substantially during the forecast period. During the forecast period, the primary growth driver in this market will be the launch of Diquas and CF101 and generally increased access to medical care for China’s enormous population.

Scope

- Overview of the DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. 
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis. 
- Sales forecast for the top drugs in China from 2012-2022. 
- Analysis of the impact of key events as well the drivers and restraints affecting China DES market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return 
- Stay ahead of the competition by understanding the changing competitive landscape for DES 
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential 
- Make more informed business decisions from insightful and in-depth analysis of drug performance 
- Obtain sales forecast for drugs from 2012-2022 in China.


To view the table of contents and know more details please visit PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022 report. 

Similar Reports:

No comments:

Post a Comment